Lv5
1270 积分 2022-08-16 加入
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases
14天前
已完结
Treatment of Cerebral Edema
15天前
已完结
290 A translatable in vivo CAR-T platform enabled by CLAMP technology for targeted mRNA delivery to T cells
1个月前
已完结
The U.S. Food and Drug Administration’s Perspective on Chimeric Antigen Receptor T-Cell Therapies for Autoimmune and Rheumatic Conditions
1个月前
已完结
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
1个月前
已完结
Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options
3个月前
已完结
Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
3个月前
已完结
Claudin 18.2 as a novel therapeutic target
4个月前
已完结
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
4个月前
已完结
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
4个月前
已完结
皖公网安备34019202002308
